HOME >> BIOLOGY >> NEWS
Cell pathways' SAANDs compounds enhance antitumor effects of Taxol™ in rodent models of breast cancer

HORSHAM, PA (April 3, 2000) -- CP461, a second generation selective apoptotic antineoplastic drug (SAAND) compound, under development by Cell Pathways, Inc. (Nasdaq: CLPA), significantly enhanced the anti-tumor activity of Taxol™ (paclitaxel) in a classic mouse model of human breast cancer, according to a presentation by company scientists this week at the annual meeting of the American Association for Cancer Research (AACR).

Cell Pathways researchers implanted human breast tumor cell lines in immunosuppressed (nude) mice and divided them into treatment and control groups. The treated mice were divided into multiple groups receiving either (1) five days of intravenous paclitaxel alone, (2) 14 days of oral CP461 at a subtherapeutic dose based on previous single agent studies, or (3) the drugs in combination. The researchers then observed the mice for 45 days. The mice tolerated the drug treatments well, whether they received the single agents or combination therapy, and there were no differences in unscheduled deaths or weight loss between the groups. The researchers observed that the reduction in the size of the tumors achieved by the combination of paclitaxel and CP461 was significantly greater (p=0.03) than that achieved with paclitaxel alone during treatment and during the month after discontinuation of treatment.

"This research suggests that CP461, given in combination with paclitaxel, may potentially increase paclitaxel1s efficacy in breast cancer without adding any additional side-effects," said Rifat Pamukcu, M.D., chief scientific officer of Cell Pathways. "CP461 is nearing completion of a Phase Ib safety study as a single agent in cancer patients. Based on these preclinical results, we plan to investigate CP461 as a single agent cancer therapy and in combination cancer chemotherapeutic studies in the near future."

CP461 is a second generation SAAND based on the mechanism of action of Aptosyn (exisulind). Aptosyn™ i
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
2-Apr-2000


Page: 1 2

Related biology news :

1. Aptosyn™ (exisulind) and other SAANDs target early event in cancer; AACR presentations detail novel apoptotic pathway
2. Exisulind (Aptosyn™) and other SAANDs compounds halt prostate cancer cell growth by two mechanisms
3. Scientists identify compounds that mimic calorie restriction
4. New, non-radioactive screen for antimalarial compounds
5. Three molecular-targeted compounds show promise against cancers
6. Emory scientists find anti-tumor compounds in magnolia cones
7. Mouse model links alcohol intake to marijuana-like brain compounds
8. Iron-binding compounds decrease body odor
9. New evidence for organic compounds in deep space
10. Researchers identify compounds that might help in spinal cord repair
11. Selected estrogen compounds modify risks of vein clotting, a response to hormone replacement theraphy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/18/2019)... ... March 18, 2019 , ... uBiome, ... industry and the third highest quality portfolio following Seres Health and Nestle, as ... Christian Moser, and Theodor Myfleler. uBiome executives Dr. Jessica Richman, PhD, co-founder and ...
(Date:3/14/2019)... , ... March 13, 2019 , ... Bode Technology (Bode), a leading provider ... on more than 100,000 sexual assault kits. As thousands of untested kits are identified ... sexual assault kit backlogs . Bode has tested more than 50,000 kits in the ...
(Date:3/12/2019)... SANTA CLARA, Calif. (PRWEB) , ... March 12, ... ... world leader in strong multi-factor authentication and combined technology all-in-one smart cards, announced ... combined with FIDO strong authentication: the Fingerprint Biometric and Dynamic CVV Payment cards. ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... WHITEHOUSE, N.J. (PRWEB) , ... March 19, 2019 , ... ... and is a great opportunity to see the most cutting-edge cancer research. The Visikol ... work with 3D cell culture assays as well as their digital ...
(Date:3/19/2019)... ... ... will review strategies for data management in modular and adaptive clinical trials. , Participants will:, ... 30 percent, reducing cost while increasing quality, achieving clinical site set-up faster , ... reducing risk and impact on trial success, trial teams, and trial execution , ...
(Date:3/15/2019)... (PRWEB) , ... March 15, ... ... of 100% equity in American Process Inc. and affiliate companies including AVAPCO ... Biorefinery in Alpena Michigan, the Thomaston Biorefinery and R&D center in Thomaston, ...
(Date:3/14/2019)... DESERT, Calif. (PRWEB) , ... March 14, 2019 ... ... issued a press release announcing that its Canadian partner, the Eye Machine Canada ... Canada, using Nova Oculus’s pioneering technology for treating Age-Related Macular Degeneration (AMD). , ...
Breaking Biology Technology:
Cached News: